The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-14-0881-t
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Dual HER2 Blockade: Preclinical and Clinical Data

Breast Cancer Research
Cancer ResearchOncology
2014English

Targeting HER2+ Breast Cancer: The TBK1/IKK-Epsilon Axis

Oncoscience
Cancer ResearchOncology
2014English

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

Clinical Cancer Research
Cancer ResearchOncology
2019English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Do Multifocal or Multicentric pT1a Node-Negative HER2+ Breast Cancers Get Benefit From Systemic Treatment?

Breast Cancer Research and Treatment
Cancer ResearchOncology
2019English

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer

Scientific Reports
Multidisciplinary
2017English

HER2-HER3 Dimer Quantification by FLIM-FRET Predicts Breast Cancer Metastatic Relapse Independently of HER2 IHC Status

Oncotarget
Oncology
2016English

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

JAMA Oncology
Cancer ResearchOncology
2019English

ZW25 Active in HER2-positive Cancers

Cancer Discovery
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy